Evidence map›Paper›PMID 41755685›Full record

ArticleJournal of diabetes investigation2026

Impact of renal function on antidiabetic drug selection in Japan: A real-world analysis using the J-DREAMS database.

Masashi Kubota, Mitsuru Ohsugi, Kohjiro Ueki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Masashi KubotaDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.ORCID https://orcid.org/0009-0003-4106-8132
Mitsuru OhsugiDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Kohjiro UekiDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1523-8102

Funding

Dainippon Sumitomo Pharma
6 · The paper itself

Abstract

aimsTo describe renal function-specific prescribing patterns of antidiabetic drugs in Japanese patients with type 2 diabetes using real-world data and to identify selection trends up to the second therapy. MATERIALS AND

methodsWe retrospectively analyzed data from the J-DREAMS registry (2015-2023) to evaluate the proportions of first and second drug classes stratified by renal function (eGFR ≥60 vs <60 mL/min/1.73 m

resultsAmong 24,868 patients, 36.1% had an eGFR <60 mL/min/1.73 m

conclusionsPrescribing patterns in Japan have shifted toward earlier use of SGLT2 inhibitors and GLP-1 receptor agonists, with medications appropriately tailored to renal function.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsKidneyPractice Patterns, Physicians'AgedDatabases, FactualDipeptidyl-Peptidase IV InhibitorsFemaleGlomerular Filtration RateGlucagon-Like Peptide-1 Receptor AgonistsHumansJapanMaleMiddle AgedRegistriesRetrospective StudiesDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsChronic renal insufficiencyDrug prescriptionsType 2 diabetes mellitus

Identifiers

PMID41755685
PMCPMC13137285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.